The Hang Seng Index Company plans to expand its biotechnology index product ecosystem

The CEO of Hang Seng Indexes Company, Wu Wanwen, stated that last year the Hang Seng Index achieved its best performance since 2017, with a year-on-year increase of 27.8%. The total assets under management (AUM) of products linked to the Hang Seng Index series reached approximately USD 117.7 billion. In the future, it will consolidate its market leadership in the technology and biotechnology sectors, expand the asset management scale tracking technology-related indices, and continue to develop biotechnology indices to support diversified product development.

The Product Director of Hang Seng Indexes Company, Lin Yingting, mentioned that the Hang Seng Biotechnology Index rose by 8.8% in January this year, outperforming the Hang Seng Composite Index's monthly increase of 7.4%, reflecting the capital market's high attention to the biotechnology sector.

She pointed out three structural drivers promoting the development of the healthcare industry, including an aging population, rising disposable income, and the potential for medical spending. At the same time, the activity level of IPOs in the healthcare industry has significantly rebounded.

Following the launch of the Hang Seng Biotechnology Index futures contracts at the end of November last year, she indicated that they will continue to expand the product ecosystem of the Hang Seng Biotechnology Index. They are currently exploring the development of more derivative products with stakeholders, including options, bull and bear certificates, and warrants, but there is no timetable yet. They are also studying the launch of more biotechnology derivative indices, such as leveraged and inverse indices